These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 10092828)

  • 1. Elimination of the immunogenicity of therapeutic antibodies.
    Gilliland LK; Walsh LA; Frewin MR; Wise MP; Tone M; Hale G; Kioussis D; Waldmann H
    J Immunol; 1999 Mar; 162(6):3663-71. PubMed ID: 10092828
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural correlates of an anticarcinoma antibody: identification of specificity-determining residues (SDRs) and development of a minimally immunogenic antibody variant by retention of SDRs only.
    Tamura M; Milenic DE; Iwahashi M; Padlan E; Schlom J; Kashmiri SV
    J Immunol; 2000 Feb; 164(3):1432-41. PubMed ID: 10640759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD52 monoclonal antibody, Campath-1H.
    Zhang Z; Zhang M; Goldman CK; Ravetch JV; Waldmann TA
    Cancer Res; 2003 Oct; 63(19):6453-7. PubMed ID: 14559836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 1.9 A structure of the therapeutic antibody CAMPATH-1H fab in complex with a synthetic peptide antigen.
    James LC; Hale G; Waldmann H; Bloomer AC
    J Mol Biol; 1999 Jun; 289(2):293-301. PubMed ID: 10366506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CAMPATH: from concept to clinic.
    Waldmann H; Hale G
    Philos Trans R Soc Lond B Biol Sci; 2005 Sep; 360(1461):1707-11. PubMed ID: 16147535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Humanization by variable domain resurfacing and grafting on a human IgG4, using a new approach for determination of non-human like surface accessible framework residues based on homology modelling of variable domains.
    Staelens S; Desmet J; Ngo TH; Vauterin S; Pareyn I; Barbeaux P; Van Rompaey I; Stassen JM; Deckmyn H; Vanhoorelbeke K
    Mol Immunol; 2006 Mar; 43(8):1243-57. PubMed ID: 16118019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved yield and stability of L49-sFv-beta-lactamase, a single-chain antibody fusion protein for anticancer prodrug activation, by protein engineering.
    McDonagh CF; Beam KS; Wu GJ; Chen JH; Chace DF; Senter PD; Francisco JA
    Bioconjug Chem; 2003; 14(5):860-9. PubMed ID: 13129388
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Engineering mouse monoclonal antibodies for cancer immunotherapy.
    Orlandi R
    Year Immunol; 1993; 7():69-73. PubMed ID: 8372514
    [No Abstract]   [Full Text] [Related]  

  • 9. Murine anti-mouse T cell monoclonal antibodies elicit anti-antibodies in mice: intra-species immunization model for estimating potential patient sensitization against humanized anti-T cell antibodies.
    Kremmer E; Mysliwietz J; Lederer R; Thierfelder S
    Eur J Immunol; 1993 May; 23(5):1017-22. PubMed ID: 8097469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduced susceptibility of recombinant polyclonal antibodies to inhibitory anti-variable domain antibody responses.
    Klitgaard JL; Coljee VW; Andersen PS; Rasmussen LK; Nielsen LS; Haurum JS; Bregenholt S
    J Immunol; 2006 Sep; 177(6):3782-90. PubMed ID: 16951339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of BR96 binding sites for antigen and anti-idiotype by codon-based scanning mutagenesis.
    Rosok MJ; Eghtedarzadeh-Kondri M; Young K; Bajorath J; Glaser S; Yelton D
    J Immunol; 1998 Mar; 160(5):2353-9. PubMed ID: 9498776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Humanization of an anti-lymphocyte function-associated antigen (LFA)-1 monoclonal antibody and reengineering of the humanized antibody for binding to rhesus LFA-1.
    Werther WA; Gonzalez TN; O'Connor SJ; McCabe S; Chan B; Hotaling T; Champe M; Fox JA; Jardieu PM; Berman PW; Presta LG
    J Immunol; 1996 Dec; 157(11):4986-95. PubMed ID: 8943405
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Somatic mutation in VH complementarity-determining region 2 and framework region 2: differential effects on antigen binding and Ig secretion.
    Wiens GD; Heldwein KA; Stenzel-Poore MP; Rittenberg MB
    J Immunol; 1997 Aug; 159(3):1293-302. PubMed ID: 9233625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Crystal structures of a rat anti-CD52 (CAMPATH-1) therapeutic antibody Fab fragment and its humanized counterpart.
    Cheetham GM; Hale G; Waldmann H; Bloomer AC
    J Mol Biol; 1998 Nov; 284(1):85-99. PubMed ID: 9811544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancement of scFv fragment reactivity with target antigens in binding assays following mixing with anti-tag monoclonal antibodies.
    Wang X; Campoli M; Ko E; Luo W; Ferrone S
    J Immunol Methods; 2004 Nov; 294(1-2):23-35. PubMed ID: 15604013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SDR grafting of a murine antibody using multiple human germline templates to minimize its immunogenicity.
    Gonzales NR; Padlan EA; De Pascalis R; Schuck P; Schlom J; Kashmiri SV
    Mol Immunol; 2004 Jul; 41(9):863-72. PubMed ID: 15261458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CDR substitutions of a humanized monoclonal antibody (CC49): contributions of individual CDRs to antigen binding and immunogenicity.
    Iwahashi M; Milenic DE; Padlan EA; Bei R; Schlom J; Kashmiri SV
    Mol Immunol; 1999; 36(15-16):1079-91. PubMed ID: 10698310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Transgenesis and humanization of murine antibodies].
    Cogné M; Duchez S; Pascal V
    Med Sci (Paris); 2009 Dec; 25(12):1149-54. PubMed ID: 20035696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Humanized anti-carcinoembryonic antigen antibody: strategies to enhance human tumor cell killing.
    Kaulen H; Seemann G; Bosslet K; Schwaeble W; Dippold W
    Year Immunol; 1993; 7():106-9. PubMed ID: 8372499
    [No Abstract]   [Full Text] [Related]  

  • 20. Helplessness as a strategy for avoiding antiglobulin responses to therapeutic monoclonal antibodies.
    Isaacs JD; Waldmann H
    Ther Immunol; 1994 Dec; 1(6):303-12. PubMed ID: 7584505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.